Back to stories
Industry

SpaceX, OpenAI and Anthropic Triple IPO Could Make 2026 Wall Street's Biggest Year Ever

Michael Ouroumis2 min read
SpaceX, OpenAI and Anthropic Triple IPO Could Make 2026 Wall Street's Biggest Year Ever

Wall Street is bracing for what bankers and analysts are calling the most concentrated IPO window in modern technology history. In coverage published on Sunday, May 17, outlets including Malay Mail summarised expectations that SpaceX, OpenAI and Anthropic could each price public offerings within roughly six months of one another — a sequence that, if it lands, would reshape index composition, retail brokerage flows and the market for AI compute capital all at once.

A roadshow calendar like no other

SpaceX is reported to be preparing a roadshow as soon as June, targeting a raise in the neighbourhood of $75 billion at a valuation that earlier reporting from TradingKey pegged at up to $1.75 trillion. OpenAI is widely expected to follow in the fourth quarter, aiming for a valuation around $1 trillion after its most recent private round closed at $852 billion on $122 billion of new capital. Anthropic, which has been raising aggressively in 2026, is reportedly targeting an October listing on the back of secondary-market valuations that recently brushed $1 trillion.

Added together, bankers cited in the coverage estimate a combined raise of more than $240 billion across the trio — a figure that dwarfs the 2014 Alibaba debut and the 2019 Saudi Aramco listing that long held the record for largest single IPO.

Retail access becomes the wild card

One reason the cluster is generating so much attention is the deliberate effort to channel shares to retail buyers. SpaceX has reportedly told underwriters it wants to reserve as much as 30% of its float for individual investors, dramatically above the 5–10% that is customary for U.S. listings. OpenAI's CFO Sarah Friar has also signalled that meaningful retail allocations are part of the plan. Anthropic has not yet detailed its approach.

For brokerages, that allocation policy raises the prospect of an unusual liquidity event — three of the most-watched private companies on earth listing in quick succession, with elevated retail demand competing for shares against the index funds and sovereign wealth pools that typically anchor deals of this size.

A stress test for the AI capital cycle

The coverage also frames the trio as a stress test for the broader AI capital cycle. Cerebras' Nasdaq debut earlier this month, which pushed the chipmaker's market capitalisation past $90 billion, has already been read as a barometer of investor appetite for pure-play AI exposure. Whether public markets can absorb three trillion-dollar-class listings on top of that — without crowding out smaller AI issuers waiting in the pipeline — is the question hanging over the back half of 2026.

Analysts quoted in the reporting cautioned that the timing is fluid: any pull-back in mega-cap tech multiples, a delay in OpenAI's restructuring, or a softer-than-expected SpaceX reception could push the calendar into 2027.

Learn AI for Free — FreeAcademy.ai

Take "AI for Business: Practical Implementation" — a free course with certificate to master the skills behind this story.

More in Industry

Google Ships Antigravity 2.0: A Standalone Agent Platform That Retires the Gemini CLI
Industry

Google Ships Antigravity 2.0: A Standalone Agent Platform That Retires the Gemini CLI

At I/O 2026, Google relaunched Antigravity as a standalone agent-orchestration platform with a CLI that replaces the Gemini CLI, an SDK, Managed Agents in the Gemini API, and an enterprise tier — all defaulting to Gemini 3.5 Flash.

10 min ago2 min read
Alibaba's Zhenwu M890 Claims 3x Nvidia's H20, Ships With Qwen 3.7-Max
Industry

Alibaba's Zhenwu M890 Claims 3x Nvidia's H20, Ships With Qwen 3.7-Max

Alibaba's chip unit T-Head unveiled the Zhenwu M890 AI accelerator, claiming 3x the agentic-inference performance of Nvidia's H20 and 144GB of HBM3, paired with the Qwen 3.7-Max model — a full domestic stack as US export controls tighten.

1 hours ago2 min read
Cohere Buys Reliant AI to Build 'North for Pharma' Sovereign Biopharma Agents
Industry

Cohere Buys Reliant AI to Build 'North for Pharma' Sovereign Biopharma Agents

Cohere has acquired Montréal- and Berlin-based biopharma startup Reliant AI, folding its automated research workbench into the North platform to launch 'North for Pharma' — its second acquisition in a month as it doubles down on sovereign, regulated-industry AI.

3 hours ago2 min read